title: Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS.
abstract: OBJECTIVE
  Conventional therapy--ie, treatment with corticosteroids and cranial radiotherapy (RT)--is inadequate to treat AIDS-related primary central nervous system lymphoma (PCNSL), as it achieves a median survival of only 2 to 5 months. Chemotherapy added to RT in non-AIDS PCNSL improves disease control and prolongs survival. We studied the efficacy of this approach with RT in AIDS-related PCNSL.
  
  
  METHODS
  Ten AIDS patients with PCNSL were treated with chemotherapy--nine at diagnosis and one at recurrence. None had evidence of systemic lymphoma. All patients treated at diagnosis received pre-RT methotrexate--eight also received thiotepa and procarbazine--followed by whole-brain RT. The patient treated at recurrence (who had been previously irradiated) received chemotherapy alone, including methotrexate, thiotepa, and procarbazine.
  
  
  RESULTS
  All had enhancing lesions on MRI and five (50%) had a single lesion (seven [70%] had a ring-enhancing mass). No patient had a response to corticosteroids. Four of seven (57%) assessable patients had a partial or complete response to chemotherapy prior to RT. Six of seven (86%) assessable patients had a complete response at the end of treatment. Median survival was 3.5 months for all 10 patients and 7 months for the eight patients who completed therapy. Two patients survived for 1 year or longer. Eight patients died--six from infection (two treatment-related), one from progressive dementia, and one from a gastrointestinal hemorrhage.
  
  
  CONCLUSIONS
  AIDS-related PCNSL responds to chemotherapy and RT, but only a few patients benefit with prolonged survival.
authors.affiliation: Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY.
authors.forename: P A
authors.initials: PA
authors.lastname: Forsyth
authors.forename: J
authors.initials: J
authors.lastname: Yahalom
authors.forename: L M
authors.initials: LM
authors.lastname: DeAngelis
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001921:Brain / Q000473:pathology; D016543:Central Nervous System Neoplasms / Q000503:physiopathology / Q000628:therapy*; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D005260:Female; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000503:physiopathology / Q000628:therapy*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local
chemical_list: D000970:Antineoplastic Agents